Navigation Links
TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
Date:12/10/2007

of patients with CLL and Cephalon expects a review decision from FDA by the end of March 2008. FDA granted orphan drug status for TREANDA for CLL in August 2007, which would entitle Cephalon to a seven-year period of marketing exclusivity for this indication in the United States, if the product is approved.

TREANDA is also being studied for the treatment of patients with indolent non-Hodgkin's lymphoma (NHL) whose disease has progressed during or following treatment with rituximab. The detailed results of this Phase 3 study also were presented during the ASH annual meeting. In addition, Cephalon has studied TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. Cephalon plans to submit an NDA for TREANDA by the end of 2007 as a single agent for the treatment of patients with indolent NHL whose disease has progressed during or following treatment with rituximab.

Cephalon holds exclusive rights to market and develop TREANDA in the United States. TREANDA is licensed from Astellas Pharma GmbH. Bendamustine HCl, the active ingredient in TREANDA, is marketed in Germany by Astellas' licensee, Mundipharma International Corporation Limited, under the tradename RIBOMUSTIN(R). In Germany, RIBOMUSTIN is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asian countries.

About Cephalon Oncology

Cephalon Oncology is a strategic business unit focused on the development and commercialization of oncology products and resources for patients and healthcare providers. The Cephalon Oncology portfolio includes a number of promising investigational and marketed compounds. In addition to TREANDA, the Cephalon Oncology therapeutic portfolio in the United States includes TRISENOX(R) (arsenic trioxide) injection, a product approved in the United Sta
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
7. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
8. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... (NADDI) today lauded the latest results achieved by ... system, known as the National Precursor Log Exchange ... law enforcement officials track down meth offenders and ... technology in Kansas blocked ...
(Date:8/20/2014)... Aug. 20, 2014 PTC Therapeutics, Inc. (NASDAQ: ... upcoming investor conferences: - FBR 1 st ... Boston on Wednesday, September 3 rd ... Mandarin Oriental Boston on Thursday, September 4 th ... at the Bank of America Merrill Lynch Global Healthcare Conference ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Personal Accident and ... Opportunities to 2018 ... provides in depth market analysis, information and ... health insurance segment, including: - The French ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2PTC Therapeutics to Participate at Upcoming Investor Conferences 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... ORLANDO, Fla. , June 30 Novo Nordisk, a ... car driver Charlie Kimball today announced the availability of ... a positive and rewarding summer camp experience.  Kimball, who has type ... attendees at the Children with Diabetes Friends for Life ...
... Biomerix Corporation announced today that it has ... to market its Biomerix Ventral Hernia Repair Mesh, the ... repair devices. The Biomerix Ventral Hernia Repair Mesh, with ... device featuring the Biomerix Biomaterial™ on one side, designed ...
Cached Medicine Technology:Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp 2Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp 3Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp 4Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp 5Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp 6Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance 2
(Date:8/21/2014)... The results of a large, retrospectives ... of the American Medical Association (JAMA) show that 3D ... unnecessary recalls. Memorial Healthcare System was one of 13 ... study confirms what we already know – 3D mammography ... to find and, at the same time, saves women ...
(Date:8/21/2014)... UK (PRWEB) August 21, 2014 The ... USD 15.6 billion in 2014 and reach USD 18.3 ... the forecast period. The drivers of such growth include ... rising obese and diabetic population, and surging ageing population. ... of state-of-the-art wound care products. Region-wise, North America leads ...
(Date:8/21/2014)... Centre, NY (PRWEB) August 21, 2014 ... mesh products manufactured by Boston Scientific has begun ... the first bellwether trial. The Rottenstein Law Group ... represents women with claims of harm stemming from ... making a claim for compensation for injuries suffered ...
(Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
(Date:8/21/2014)... The Swedish-American Life Science Summit, (SALSS) ... on the Future of Medicine and the challenges ... , With the mission to turn new sciences ... business and science. "Over the years SALSS has ... diverse community with representatives challenging the boundaries of ...
Breaking Medicine News(10 mins):Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2
... 28, 2009 (BRONX, NY) A laboratory study by ... suggests that an anti-cancer compound studied for treating blood cancers ... neck. The work is reported in the April 28th online ... and neck cancer refers to tumors in the mouth, throat, ...
... studies used to gain Food and Drug Administration approval of ... according to a report led by the University of Pittsburgh ... of the American Journal of Psychiatry , the study ... for these studies, and those who do not qualify are ...
... April 28 With growing concerns about the current ... raised, "Will face masks protect against swine flu?"Tony Hanson, ... of ProGear(TM), an innovative, technologically advanced system of medical ... stated, "At this time it is believed that the ...
... CAMBRIDGE, Mass., April 28 Gene Network Sciences, Inc. ... President of Wyeth Research & Development and a leader ... Ruffolo retired as President of Wyeth Research & Development ... Wyeth. He had joined Wyeth in November 2000 and ...
... to Embrace Use of Targeted Agents Despite Their ... Resources WALTHAM, Mass., April 28 Decision Resources, ... firms focusing on pharmaceutical and healthcare issues, finds ... Xeloda, Indian brand/generics (capecitabine) will dominate the Indian ...
... and the man, urge advocacy groups worldwideCHICAGO, April 28 ... management and treatment are needed, according to influential prostate ... American Urological Association annual meeting. In particular, a Charter ... draws attention to the impact of prostate cancer on ...
Cached Medicine News:Health News:Experimental drug shows promise against head and neck cancer 2Health News:Are we cherry picking participants for studies of antidepressants? 2Health News:Will Face Masks Protect Against Swine Flu? 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2Health News:Living and Loving with Prostate Cancer: Men Deserve Better 2Health News:Living and Loving with Prostate Cancer: Men Deserve Better 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: